Table 1.
Antibody–drug conjugates (ADCs) approved by the Food and Drug Administration (FDA), in advanced clinical trials (Phase III or pivotal phase II) or recently stopped.
| Company | ADC (Cytotoxic) | Isotype and Target | Indication/Approval Date (Trade Name)/Clinical Status |
|---|---|---|---|
| Pfizer | gemtuzumab ozogamicin (CAL) | IgG4 CD33 | 2000–2010/2017 AML (Mylotarg®) |
| Seattle Genetics | brentuximab vedotin (AUR) | IgG1 CD30 | 2011 ALCL and Hodgkin lymphoma (Adcetris®) |
| Roche | trastuzumab emtansine (MAY) | IgG1 HER2+ | 2013 metastatic HER2+++ breast cancer (Kadcyla®) ** |
| Pfizer | inotuzumab ozogamicin (CAL) | IgG4 CD22 | 2017 ALL and CLL (Besponsa®) |
| Roche | polatuzumab vedotin (AUR) | IgG1 CD79b | 2019 DLBCL (Polivy®) |
| Seattle Genetics | enfortumab vedotin (AUR) | IgG1 Nectin 4 | 2019 urothelial cancer (Padcev®) ** |
| Daiichi Sankyo | trastuzumab deruxtecan (EXA) | IgG1 HER2+ | 2019 metastatic HER2+++ breast cancer (Enhertu®) ** |
| Immunomedics | sacituzumab govitecan (IRI) | IgG1 TROP-2 | 2020, metastatic TNBC (Trodelvy®) ** |
| GSK | belantamab mafodotin (AUR, MMAF) | IgG1afuc BCMA | 2020, multiple myeloma (Blenrep®) |
| Byondis * | trastuzumab duocarmazine (DUO) | IgG1 HER2+ | Ph 3 metastatic HER2+++ breast cancer (vs T-DM1) ** |
| Bio-Thera | BAT8001 (MAY) | IgG1 HER2+ | Ph 3 breast cancer HER2+++ (vs T-DM1) ** |
| ImmunoGen | mirvetuximab soravtansine (MAY) | IgG1 Folate R1 | Ph 3 epithelial ovarian cancer ** |
| Sanofi (IMG) | SAR408701 (MAY, DM4) | IgG1 CEACAM5 | Ph 3 metastatic small cell lung cancer ** |
| ADC-Therapeutics | loncastuximab tesirine (PBD) | IgG1 CD19 | Piv. Ph2 diffuse large B-Cell lymphoma (BLA 2H2020) |
| ADC-Therapeutics | camidanlumab tesirine (PBD) | IgG1 CD25 | Pivotal Ph2 Hodgkin lymphoma |
| Seattle Genetics | vadastuximab talirine (PBD) | IgG1 CD33 | Ph 3 AML (stopped, 2017) |
| AbbVie | rovalpituzumab tesirine (PBD) | IgG1 DLL3 | Ph 3 small cell lung cancer (stopped, 2019) ** |
| AbbVie | depatuxizumab mafodotin (AUR) | IgG1 EGFRvIII | Ph 3 glioblastome (stopped, 2019) ** |
* formerly Synthon Biopharmaceuticals, ** ADC targeting solid tumor.